Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.
Padkin
A
A
Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene, London, UK. Andrew.Padkin@lshtm.ac.uk
Rowan
K
K
Black
N
N
D000925:Anticoagulants / Q000627:therapeutic use*; D002985:Clinical Protocols; D003422:Critical Care / Q000379:methods*; D016208:Databases, Factual; D019317:Evidence-Based Medicine / Q000379:methods*; D006801:Humans; D011050:Policy Making; D011486:Protein C / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*
D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins